Samaritan Pharmaceuticals

Samaritan Pharmaceuticals patent-pending products are built upon a, cholesterol-metabolism and glucocorticoid-biosynthesis, technology platform. Our hypothesis is the regulation of endogenous steroid synthesis is thought to be a successful therapeutic approach to treat various steroid-dependent pathologies such as Alzheimer's, Anxiety Disorders, Cancer, Depression, High Cholesterol and HIV.
The research and development, that separates Samaritan, is in the areas of drugs to inhibit glucocorticoid-mediated neurotoxicity and protect against beta amyloid-induced neurotoxicity.

Samaritan Pharmaceuticals' Phase II drug is an upgraded formulation of Procaine, which is "risk contained" being a proven drug, with data on record, as to its therapeutic efficacy and toxicity, since it was approved by the US FDA quite a while ago.

Activity:

- Licensing & Business Development
- Regulatory Affairs & Legal Services
- Research & Development

Product / Technology type(s) covered:

- Diagnostics
- FP (finished products)
- NCE (new chemical entities)
- Pharmaceuticals / Therapeutics
- Proteins

Therapeutic targets:

- Alzheimer's Disease
- Cancer
- Central nervous system
- Infectious Diseases
- Neurology

Markets Covered

a. HeadQuarter: United States of America

b. Continent(s) active: North America , Europe , Far East , Australia/New-Zealand

c. Countries active: North America

Corporate data:

Number of Employees: 24

Turnover:

Amount:	Year:	Currency:
0	2001	US Dollar

Year founded: 1997

Stock options:

	Symbol	Exchange
1	SPHC	OTC:BB

Partners / Alliances: Georgetown University